Effect of ganciclovir eye-drops for corneal endothelitis caused by cytomegalovirus infection

Effect of antiviral agent against cytomegalovirus corneal endothelitis - Effect of antiviral agent against cytomegalovirus corneal endothelitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs021180030

Enrollment

100

Registered

2019-03-25

Start date

2016-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus coreal endotheliitis Cytomegalovirus, Coreal endotheliitis

Interventions

0.5% Ganciclovir eye-drops (4-6 times/day)

Ganciclovir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cytomegalovirus coreal endotheliitis established by the Japan Corneal Endotheliitis Study Group which was authorised by the Japanese Ministry of Health, Labour and Welfare

Exclusion criteria

Exclusion criteria: Patients which did not agree to join this clinical trial

Design outcomes

Primary

Measure	Time frame
Corneal condition	—

Secondary

Measure	Time frame
Intraocular pressure, Corneal endothelial cells	—

Contacts

Public ContactToshio Tando

Hirosaki University

ttando7@hirosaki-u.ac.jp+81-172395095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026